Journal
APOPTOSIS
Volume 14, Issue 4, Pages 409-423Publisher
SPRINGER
DOI: 10.1007/s10495-008-0306-6
Keywords
Apoptosis; Leukemia; Lymphoma; TRAIL; IAPs; Bcl-2
Categories
Funding
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Bundesministerium fur Forschung und Technologie
- Wilhelm-Sander-Stiftung
- Else-Kroner-Fresenius Stiftung
- European Community [ApopTrain, APO-SYS]
- DAAD/INCA
- IAP6/18
Ask authors/readers for more resources
Evasion of apoptosis is a hallmark of human cancers, for example in hematological malignancies. Apoptosis is an intrinsic cell death program that is crucial to maintain tissue homeostasis, for example in the hematopoietic system where there is a high turnover rate of cells. As a result, a decrease in the rate of apoptosis besides an increase in proliferation favors tumorigenesis as well as tumor progression. Further, the anti-leukemic action of current treatment approaches, including chemo-, radio- or immunotherapy, critically relies on intact cell death programs in cancer cells. Therefore, defects in apoptosis pathways are frequently associated with the resistance to anticancer therapies. In recent years, the identification and characterization of the molecules and pathways that are involved in the regulation and execution of cell death in leukemia and lymphoma cells have set the ground for the development of novel diagnostic tools and molecular therapeutics targeting apoptosis pathways in hematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available